About
News & Events

News

RareCyte® Secures $24M Financing to Advance the Orion Spatial Biology Platform and Expand Global Commercial Channels

Seattle, WA, September 9, 2021 – RareCyte, Inc. (“RareCyte” or “the Company”) a Life Sciences company developing and manufacturing proprietary platforms enabling precision biology solutions, announced today the completion of a $24M financing from new and existing investors. The funding will drive the commercialization and applications for the Company’s new Orion spatial biology platform and further global expansion for the Company’s portfolio of instruments and consumables.

Read more...

RareCyte announces new rare cell detection kit for non-epithelial cancers

Seattle, WA, September 7, 2021 – RareCyte® announces a new rare cell detection kit, The Cell Discovery Kit, which enables custom panel development in your lab for the detection of circulating tumor cells (CTCs) that do not express epithelial markers, such as sarcomas and melanoma, as well as other non-tumor rare cell populations. Together with the AccuCyte® Sample Preparation System, the Cell Discovery Kit provides sensitive and specific rare cell identification.

Read more...

RareCyte announces new Synaptophysin CTC assay for blood-based characterization of treatment-resistant malignancies

Seattle, WA, June 01, 2021 – RareCyte® announces a new biomarker liquid biopsy assay for the neuroendocrine marker, synaptophysin (SYP), enabling customers to evaluate SYP expression on circulating tumor cells (CTCs) with industry leading accuracy and precision in patients with prostate cancer.

Read more...

RareCyte announces first commercially available ARv7/Synaptophysin CTC assay for blood-based characterization of treatment resistant prostate cancer

Seattle, WA, August 26, 2020 – RareCyte® announces a new dual biomarker liquid biopsy assay for androgen receptor splice variant 7 (ARv7) and the neuroendocrine marker, synaptophysin (SYP), enabling customers to evaluate both ARv7 and SYP expression on circulating tumor cells (CTCs) with industry leading accuracy and precision in patients with prostate cancer.

Read more...

RareCyte® announces the Orion spatial biology platform with breakthrough technology for same-day highly multiplexed tissue analysis

Seattle, WA. July 16, 2020 – RareCyte, Inc., a company focused on providing Precision Biology solutions for life sciences, announced today the Orion spatial biology analysis platform applicable to translational and clinical research. Orion is based on a patented and proprietary technology that will accelerate immuno-oncology and infectious disease research. Orion enables comprehensive phenotypic profiling and spatial analysis of the tissue microenvironment in a matter of hours, in contrast to existing technologies that require several days to weeks.

Read more...

Events

Oral Presentation during ACTC
Arturo Ramirez, Ph.D., Director of Oncology for RareCyte, will be presenting "Comprehensive CTC analysis: Generating more information from liquid biopsies" as part of the day one program at 3:00 pm EET.

Booth # 718

Booth # 1109

Joe Victor, RareCyte CEO presented at the Life Science Innovation NW conference July 16 including an announcement of the launch of the breakthrough Orion Spatial Biology platform.